Data from a new study show the importance of taking preventative measures against contracting human papillomavirus, including urging patients to get the HPV vaccine.
Researchers assessed whether patients with head and neck cancer who had higher levels of tumor-infiltrating lymphocytes had better survival rates.
Researchers compared the swallowing-related quality-of-life scores of patients with oropharyngeal squamous cell carcinoma who received radiotherapy and patients who received transoral robotic surgery with neck dissection.
A new study looked at what methods were used to detect recurrences of human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma to see if surveillance guidelines recommended by the National Comprehensive Cancer Center were effective.
Researchers surveyed patients who underwent surgery for thyroid cancer and found a high number reported voice abnormalities post-operation.
Potential new developments have been made in detecting sentinel lymph nodes for patients with localized oral cancers.
The FDA approved pembrolizumab for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma.
The phase III KEYNOTE-048 study compared pembrolizumab plus chemotherapy vs the EXTREME regimen in patients with recurrent/metastatic head and neck cancer.
Experts discuss the PD-1 checkpoint inhibitors nivolumab and pembrolizumab in the management of head and neck cancer, and how to choose between them.
Erin McMenamin, CRNP, of Penn Medicine, discusses how oral side effects affect head and neck cancer patients.